26905-02-2

Basic information

• Product Name: 4-(4-CHLOROPHENYL)PIPERIDINE
• Synonyms: 4-(4-CHLOROPHENYL)PIPERIDINE;Piperidine, 4-(4-chlorophenyl)-
• CAS NO: 26905-02-2
• Molecular Formula: C₁₁H₁₄ClN
• Molecular Weight: 195.69
• Mol File: 26905-02-2.mol

Chemical Properties

• Melting Point: 0°C
• Boiling Point: 0°C
• Flash Point: 0°C
• Appearance: /
• Density: 1.095 g/cm³
• Vapor Pressure: 0.00204mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: 2-8°C(protect from light)
• Solubility: soluble in Methanol
• PKA: 10.14±0.10(Predicted)
• CAS DataBase Reference: 4-(4-CHLOROPHENYL)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-CHLOROPHENYL)PIPERIDINE(26905-02-2)
• EPA Substance Registry System: 4-(4-CHLOROPHENYL)PIPERIDINE(26905-02-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 26905-02-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-CHLOROPHENYL)PIPERIDINE is used as a building block in organic synthesis for the development of new pharmaceutical compounds. Its unique structure and properties make it a valuable component in the creation of innovative drugs.
Used in Medicinal Chemistry Research:
4-(4-CHLOROPHENYL)PIPERIDINE is used as a pharmaceutical intermediate for the synthesis of various medicinal agents. Its potential role in the treatment of neurological and psychiatric disorders is currently under investigation, highlighting its importance in advancing therapeutic options for these conditions.
Used in Drug Development for Neurological and Psychiatric Disorders:
4-(4-CHLOROPHENYL)PIPERIDINE is employed as a key component in the development of drugs targeting neurological and psychiatric disorders. Its potential therapeutic applications are being studied to explore its efficacy in managing such conditions, thereby contributing to the improvement of patient care and treatment outcomes.

InChI:InChI=1/C11H14ClN/c12-11-3-1-9(2-4-11)10-5-7-13-8-6-10/h1-4,10,13H,5-8H2

Upstream product

• 143866-70-0 N-benzyl-4-(4-chlorophenyl)-piperidine 
• 694-05-3 1,2,3,6-tetrahydropyridine 
• 108-90-7 chlorobenzene 
• 30005-58-4 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 41979-39-9 4-piperidone hydrochloride 
• 873-77-8 (4-chlorphenyl)magnesium bromide 
• 56108-25-9 N-benzyl-4-(4-chlorophenyl)-4-hydroxypiperidin 
• 231958-20-6 4-(4-chlorophenyl)-1,2,3,6-tetrahydro-1-(phenylmethyl)-pyridine 
• 138647-50-4 4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 74901-69-2 2,4-dichloro-6,7-dihydro-thieno[3,2-d]pyrimidine 
• 1146361-96-7 (R)-1-(2-chloro-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-ylamino)-1-(4-fluorophenyl)-2-methylpropan-2-ol 
• 1143575-87-4 [1-(2-chloro-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-ylamino)-cyclopropyl]-methanol 
• 1143575-85-2 (2-chloro-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-yl)-(tetrahydropyran-4-yl)-amine 

Downstream Products

• 133229-04-6 1-[4-(4-Chloro-phenyl)-piperidin-1-yl]-3-(4-nitro-phenoxy)-propan-2-ol 
• 866785-01-5 {3-[4-(4-chlorophenyl)-piperidine-1-sulfonyl]-4-methyl-phenyl}-acetic acid ethyl ester 
• 374812-79-0 tert-Butyl 8-[3-[4-(4-chlorophenyl)-1-piperidinyl] propoxy]-1,3,4,5-tetrahydro-2H-2-benzazepine-2-carboxylate 
• 1189532-94-2 2-(4-(4-chlorophenyl)piperidin-1-yl)-8-hydroxynaphthalene-1,4-dione 
• 952055-91-3 2-[4-(4-Chloro-phenyl)-piperidin-1-ylmethyl]-1-methyl-1H-benzoimidazole 
• 1241898-79-2 ethyl (5-{2-[4-(4-chlorophenyl)piperidin-1-yl]-1,3-thiazol-5-yl}-2H-tetrazol-2-yl)acetate 
• 1146355-27-2 (R)-2-{2-[4-(4-chlorophenyl)-piperidin-1-yl]-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-ylamino}-pentan-1-ol 
• 1242411-16-0 C₂₄H₃₉ClN₂ 
• 1261171-55-4 C₁₉H₂₁ClN₂O₂ 
• 1323404-14-3 3-(4-((3-((4-(4-CHLOROPHENYL)PIPERIDIN-1-YL)METHYL) BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE 
• 1341229-48-8 C₂₉H₃₁ClFNO₃*ClH 
• 1341229-16-0 C₂₉H₃₁ClFNO₃*ClH 

Relevant articles and documents

TRPML MODULATORS

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

20-HETE FORMATION INHIBITORS

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents

Epilepsy is a kind of disease with complicated pathogenesis. KCNQ (Kv7) is a voltage dependent potassium channel that is mostly associated with epilepsy and thus becomes an important target in the treatment of epilepsy. In this paper, a series of substituted piperidine derivatives targeting KCNQ were designed and synthesized by using scaffold hopping and active substructure hybridization. Compounds were evaluated by fluorescence-based thallium influx assay, Rb+ flow assay and electrophysiological patch-clamp assay. Results showed that some compounds possessed more potent potassium channel opening activity than Retigabine. More significantly, compound 11 was found to have good pharmacokinetic profiles in vivo.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

4-Aryl piperazine and piperidine amides as novel mGluR5 positive allosteric modulators

Positive allosteric modulation of metabotropic glutamate receptor 5 (mGluR5) is regarded as a potential novel treatment for schizophrenic patients. Herein we report the synthesis and SAR of 4-aryl piperazine and piperidine amides as potent mGluR5 positive allosteric modulators (PAMs). Several analogs have excellent activity and desired drug-like properties. Compound 2b was further characterized as a PAM using several in vitro experiments, and produced robust activity in several preclinical animal models.

New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture

The present invention relates to carboxamide compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1, R2, R3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Design, Synthesis, and Evaluation of Metabolism-Based Analogues of Haloperidol Incapable of Forming MPP+-like Species

The long-term, irreversible, Parkinsonism-like side effects of haloperidol have been speculated to involve several mechanisms. More recently, it has been speculated that the metabolic transformation to MPP+-like species may contribute to the Parkinsonism-like side effects. Because BCPP+ and its reduced analogue have been shown to possess the potential to destroy dopamine receptors in the nigrostriatum, we have designed new analogues of haloperidol lacking the structural features necessary to form neurotoxic quaternary species but retaining their dopamine-binding capacity. The most potent agent at the D2 receptor, the homopiperidine analogue 11, was found to be equipotent to haloperidol. It was also of interest to identify analogues with DA binding profiles similar to that of clozapine at the dopamine receptor subtypes. Evaluation of the proposed agents shows that the ratio of D2 to D4 (2) binding of clozapine was mimicked by 7 [Ki(D2) = 33, Ki(D3) = 200, Ki(D4) = 11 nM; Ki(D2)/Ki(D4) = 3] and 9 [Ki(D2) = 44, Ki(D3) = 170, Ki(D4) = 24 nM; Ki(D2)/Ki(D4) = 2]. A preliminary in-vivo testing of compound 7 shows that its behavioral profile is similar to that of clozapine. This profile suggests that there is a need for further evaluation of these two synthetic agents and their enantiomers for efficacy and lack of catalepsy in animal models.